An Entry to Novel Platinum Complexes: Carboxylation of Dihydroxoplatinum(IV) Complexes with Succinic Anhydride and Subsequent Derivatization

No abstract is available for this paper.

• Publication year

  2006

• Venue

  European Journal of Inorganic Chemistry

• Publication date

  2006-07-01

• Fields of study

  Chemistry

• Identifiers
  DOI 10.1002/EJIC.200600108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.

  2005cited by this paper
• Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: influence of the ligands on drug efficacies and uptake.

  2005cited by this paper
• Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.

  2005cited by this paper
• Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches.

  2005cited by this paper
• New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes

  2004cited by this paper
• Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes.

  2004cited by this paper
• Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.

  2004cited by this paper
• Platinum(IV) anticancer complexes.

  2004cited by this paper
• Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

  2004cited by this paper
• Tumour-inhibiting platinum complexes--state of the art and future perspectives.

  2003cited by this paper
• Platinum(IV) antitumour compounds: their bioinorganic chemistry

  2002cited by this paper
• Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.

  2002cited by this paper
• Carboxylation of 2-Hydroxyethyl-Substituted Tetrachloro(ethane-1,2-diamine)platinum(IV) Complexes — A New Synthetic Approach to Anticancer Platinum Compounds

  2002cited by this paper
• Platinum complexes for the treatment of cancer

  2001cited by this paper
• Reduction and Anticancer Activity of Platinum(IV) Complexes

  1998cited by this paper
• Carboxylation of dihydroxoplatinum(IV) complexes with acyl chlorides. Crystal structures of the trans-R,R- and trans-S,S-isomer of (OC-6-33)-bis(1-adamantanecarboxylato)-(cyclohexane-1,2-diamine)dichloroplatinum(IV)

  1997cited by this paper
• Carboxylation of Dihydroxoplatinum(IV) Complexes via a New Synthetic Pathway.

  1996cited by this paper
• Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

  1995cited by this paper
• Synthesis and Characterization of New Ethylenediamine Platinum(IV) Complexes Containing Lipophilic Carboxylate Ligands

  1995cited by this paper
• The Influence of the Axial Ligands of a Series of Platinum(IV) Anti-Cancer Complexes on Their Reduction to Platinum(II) and Reaction With DNA

  1995cited by this paper
• Preparation, characterization, and antitumor activity of new ethylenediamine platinum(IV) complexes containing mixed carboxylate ligands.

  1993cited by this paper
• International tables for X-ray crystallography

  1962cited by this paper

• Construction of succinoglycan riclin-Pt (IV) conjugates for carrying resveratrol: a potential tool for biomedical applications

  2026cites this paper
• Pt(IV) prodrugs containing aliphatic amine in axial ligands with anticancer properties: Advanced synthesis, solubility, reduction, cytotoxicity, cell mechanism, DNA interaction, molecular docking, and molecular dynamics simulations.

  2025cites this paper
• Peptide-Platinum(IV) Conjugation Minimizes the Negative Impact of Current Anticancer Chemotherapy on Nonmalignant Cells.

  2023cites this paper
• A novel therapy to combat non-small cell lung carcinoma (A549) using platinum (IV) and barium titanate conjugate

  2022cites this paper
• Dual-Action Pt(IV) Prodrugs and Targeted Delivery in Metal-Organic Frameworks: Overcoming Cisplatin Resistance and Improving Anticancer Activity

  2022cites this paper
• Traceable Nanocluster-Prodrug Conjugate for Chemo-photodynamic Combinatorial Therapy of Non-small Cell Lung Cancer.

  2021cites this paper
• Multifunctional Pt(IV) prodrug candidates featuring the carboplatin core and deferoxamine.

  2021cites this paper
• Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance

  2020cites this paper
• Glucose-modification of cisplatin to facilitate cellular uptake, mitigate toxicity to normal cells, and improve anti-cancer effect in cancer cells

  2020cites this paper
• PEGylated nano-graphene oxide as a nanocarrier for delivering mixed anticancer drugs to improve anticancer activity

  2020cites this paper
• Conjugation between maleimide-containing Pt(IV) prodrugs and furan or furan-containing drug delivery vectors via Diels-Alder cycloaddition

  2019cites this paper
• Antiproliferative activity of Pt(IV) complexes with lonidamine and bexarotene ligands attached via succinate-ethylenediamine linker

  2019cites this paper
• A view on multi-action Pt(IV) antitumor prodrugs

  2019cites this paper
• pH/redox dual-sensitive platinum (IV)-based micelles with greatly enhanced antitumor effect for combination chemotherapy.

  2019cites this paper
• Current Status for Oral Platinum (IV) Anticancer Drug Development

  2018cites this paper
• Bioorthogonal photocatalytic activation of metal-based anticancer agents

  2018cites this paper
• A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes.

  2018cites this paper
• Development and Validation of Liquid Chromatography-Based Methods to Assess the Lipophilicity of Cytotoxic Platinum(IV) Complexes

  2018influential citation
• Folate-decorated and NIR-triggered nanoparticles loaded with platinum(IV)-prodrug plus 5-fluorouracil for targeted and chemo-photothermal combination therapy

  2018cites this paper
• Recent progress in polymer-based platinum drug delivery systems

  2018cites this paper
• Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.

  2018cites this paper
• Folate-decorated and NIR-activated nanoparticles based on platinum(IV) prodrugs for targeted therapy of ovarian cancer

  2017cites this paper
• Novel Cu(II) complexes of bithiazole: structure and biological study

  2017cites this paper
• Riboflavin as a bioorthogonal photocatalyst for the activation of a PtIV prodrug

  2017cites this paper
• Impact of the equatorial coordination sphere on the rate of reduction, lipophilicity and cytotoxic activity of platinum(IV) complexes.

  2017cites this paper
• Platinum(IV) prodrug conjugated Pd@Au nanoplates for chemotherapy and photothermal therapy.

  2016cites this paper
• The role of the equatorial ligands for the redox behavior, mode of cellular accumulation and cytotoxicity of platinum(IV) prodrugs.

  2016cites this paper
• Encapsulation of lipophilic kiteplatin Pt(iv) prodrugs in PLGA-PEG micelles.

  2016cites this paper
• A dextran-platinum(iv) conjugate as a reduction-responsive carrier for triggered drug release.

  2015cites this paper
• Recent Advances in Platinum (IV) Complex‐Based Delivery Systems to Improve Platinum (II) Anticancer Therapy

  2015cites this paper
• Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.

  2015cites this paper
• Bis‐ and Tetrakis(carboxylato)platinum(IV) Complexes with Mixed Axial Ligands – Synthesis, Characterization, and Cytotoxicity

  2015cites this paper
• Incorporation of cisplatin into the metal–organic frameworks UiO66-NH2 and UiO66 – encapsulation vs. conjugation

  2015cites this paper
• Bis- and Tris(carboxylato)platinum(IV) Complexes with Mixed Am(m)ine Ligands in the trans Position Exhibiting Exceptionally High Cytotoxicity

  2015cites this paper
• From proton transferred to cyclometalated platinum(IV) complex: Crystal structure and biological activity

  2015cites this paper
• Thermogelling polymer-platinum(IV) conjugates for long-term delivery of cisplatin.

  2015cites this paper
• Synthesis and characterization of hyaluronic acid–platinum(IV) nanoconjugate with enhanced antitumor response and reduced adverse effects

  2015cites this paper
• Reinterpretation of the vibrational spectroscopy of the medicinal bioinorganic synthon c,c,t-[Pt(NH3)2Cl2(OH)2]

  2014cites this paper
• Elemental imaging and biological activity of tumor-inhibiting platinum compounds

  2014cites this paper
• Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment.

  2014cites this paper
• Comparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application

  2014cites this paper
• Platinum(IV) Complexes Featuring One or Two Axial Ferrocene Bearing Ligands – Synthesis, Characterization, and Cytotoxicity

  2014cites this paper
• Platinum(IV) Complexes Featuring Axial (1, 4–13C2)Succinato Ligands – Synthesis, Characterization, and Preliminary ­Investigations in Cancer Cell Lysates

  2013cites this paper
• A fluorescent probe for investigating the activation of anticancer platinum(IV) prodrugs based on the cisplatin scaffold.

  2013cites this paper
• Bulky N(,N)-(di)alkylethane-1,2-diamineplatinum(II) compounds as precursors for generating unsymmetrically substituted platinum(IV) complexes.

  2013cites this paper
• NMR investigation of the spontaneous thermal- and/or photoinduced reduction of trans dihydroxido Pt(IV) derivatives.

  2013cites this paper
• Synthesis and characterization of Novel Di- and Tetracarboxylatoplatinum(IV) complexes

  2013cites this paper
• A core cross-linked polymeric micellar platium(IV) prodrug with enhanced anticancer efficiency.

  2013cites this paper
• Synthetic methods for the preparation of platinum anticancer complexes.

  2013cites this paper
• Monofunctional and higher-valent platinum anticancer agents.

  2013cites this paper
• Mesoporous silica nanoparticle-based cisplatin prodrug delivery and anticancer effect under reductive cellular environment.

  2013cites this paper
• Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(IV) prodrugs.

  2012cites this paper
• Modulation of Ligand Fluorescence by the Pt(II)/Pt(IV) Redox Couple.

  2012cites this paper
• Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.

  2012cites this paper
• Oxidative Reactivity and Cytotoxic Properties of a Platinum(II) Complex Prepared by Outer-Sphere Amide Bond Coupling.

  2012cites this paper
• Diamminetetrakis(carboxylato)platinum(IV) Complexes – Synthesis, Characterization, and Cytotoxicity

  2012cites this paper
• Theoretical Investigations and Density Functional Theory Based Quantitative Structure–Activity Relationships Model for Novel Cytotoxic Platinum(IV) Complexes

  2012cites this paper
• Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates.

  2012cites this paper
• Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.

  2012cites this paper
• The use of polymeric platinum(IV) prodrugs to deliver multinuclear platinum(II) drugs with reduced systemic toxicity and enhanced antitumor efficacy.

  2012cites this paper
• What do we know about the reduction of Pt(IV) pro-drugs?

  2012cites this paper
• Synthesis and cytotoxicity of diam(m)ineplatinum(II) complexes with 2,2-bis(hydroxymethyl)malonate as the leaving group.

  2012cites this paper
• Platinum (IV)-coordinate polymers as intracellular reduction-responsive backbone-type conjugates for cancer drug delivery.

  2011cites this paper
• Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II).

  2011cites this paper
• New Trends and Future Developments of Platinum‐Based Antitumor Drugs

  2011cites this paper
• Synthesis, characterization and cytotoxicity of a series of tetrachloridoplatinum(IV) complexes

  2011cites this paper
• Mono-carboxylated diaminedichloridoplatinum(IV) complexes--selective synthesis, characterization, and cytotoxicity.

  2011cites this paper
• Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin

  2011cites this paper
• The first example of MEEKC‐ICP‐MS coupling and its application for the analysis of anticancer platinum complexes

  2010cites this paper
• Novel bis(carboxylato)dichlorido(ethane-1,2-diamine)platinum(IV) complexes with exceptionally high cytotoxicity.

  2008cites this paper
• Drug Delivery Devices and Targeting Agents for Platinum(II) Anticancer Complexes

  2008cites this paper
• Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.

  2008cites this paper
• Novel Endothall‐Containing Platinum(IV) Complexes: Synthesis, Characterization, and Cytotoxic Activity

  2008cites this paper
• Unprecedented twofold intramolecular hydroamination in diam(m)ine-dicarboxylatodichloridoplatinum(IV) complexes - ethane-1,2-diamine vs. ammine ligands.

  2008cites this paper
• 195Pt NMR--theory and application.

  2007cites this paper